LadRx Corporation (LADX)
USD 1.49
(-2.61%)
USD 1.49
(-2.61%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.81 Million USD | -16.15% |
| 2022 | 4.56 Million USD | -23.75% |
| 2021 | 5.97 Million USD | -12.44% |
| 2020 | 6.82 Million USD | -13.13% |
| 2019 | 7.86 Million USD | -7.49% |
| 2018 | 8.49 Million USD | -74.23% |
| 2017 | 32.97 Million USD | -37.15% |
| 2016 | 52.45 Million USD | -17.23% |
| 2015 | 63.37 Million USD | 27.51% |
| 2014 | 49.7 Million USD | 78.19% |
| 2013 | 27.89 Million USD | 31.88% |
| 2012 | 21.15 Million USD | -7.65% |
| 2011 | 22.9 Million USD | 35.92% |
| 2010 | 16.85 Million USD | -1.72% |
| 2009 | 17.14 Million USD | -22.15% |
| 2008 | 22.02 Million USD | -35.07% |
| 2007 | 33.91 Million USD | 72.47% |
| 2006 | 19.66 Million USD | 25.03% |
| 2005 | 15.72 Million USD | 12.2% |
| 2004 | 14.01 Million USD | 23.2% |
| 2003 | 11.37 Million USD | 96.93% |
| 2002 | 5.77 Million USD | 9.84% |
| 2001 | 5.26 Million USD | 16.24% |
| 2000 | 4.52 Million USD | -72.84% |
| 1999 | 16.66 Million USD | 61.79% |
| 1998 | 10.3 Million USD | -32.24% |
| 1997 | 15.2 Million USD | 83.13% |
| 1996 | 8.3 Million USD | -25.89% |
| 1995 | 11.2 Million USD | 4.67% |
| 1994 | 10.7 Million USD | 35.44% |
| 1993 | 7.9 Million USD | 54.9% |
| 1992 | 5.1 Million USD | 96.15% |
| 1991 | 2.6 Million USD | 85.71% |
| 1990 | 1.4 Million USD | -46.15% |
| 1989 | 2.6 Million USD | -60.61% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1.29 Million USD | 56.0% |
| 2024 Q1 | 829.83 Thousand USD | -5.61% |
| 2023 Q1 | 1.08 Million USD | 13.7% |
| 2023 Q4 | 879.15 Thousand USD | 4.58% |
| 2023 Q3 | 840.62 Thousand USD | -17.67% |
| 2023 Q2 | 1.02 Million USD | -5.46% |
| 2023 FY | 3.81 Million USD | -16.41% |
| 2022 FY | 4.56 Million USD | -23.75% |
| 2022 Q1 | 1.29 Million USD | -34.79% |
| 2022 Q2 | 1.14 Million USD | -11.35% |
| 2022 Q4 | 949.83 Thousand USD | -18.65% |
| 2022 Q3 | 1.16 Million USD | 1.7% |
| 2021 Q1 | 1.28 Million USD | -10.09% |
| 2021 Q3 | 1.53 Million USD | 29.81% |
| 2021 Q2 | 1.18 Million USD | -7.73% |
| 2021 Q4 | 1.98 Million USD | 29.55% |
| 2021 FY | 5.97 Million USD | -12.44% |
| 2020 Q2 | 1.37 Million USD | 12.45% |
| 2020 Q4 | 1.42 Million USD | -49.17% |
| 2020 Q1 | 1.22 Million USD | -59.74% |
| 2020 Q3 | 2.8 Million USD | 103.1% |
| 2020 FY | 6.82 Million USD | -13.13% |
| 2019 Q3 | 1.54 Million USD | 0.98% |
| 2019 FY | 7.86 Million USD | -7.49% |
| 2019 Q4 | 3.04 Million USD | 96.94% |
| 2019 Q2 | 1.53 Million USD | -11.87% |
| 2019 Q1 | 1.73 Million USD | 244.51% |
| 2018 Q2 | 2.5 Million USD | -36.0% |
| 2018 Q3 | 3.27 Million USD | 30.38% |
| 2018 Q4 | -1.2 Million USD | -136.77% |
| 2018 Q1 | 3.91 Million USD | -31.96% |
| 2018 FY | 8.49 Million USD | -74.23% |
| 2017 FY | 32.97 Million USD | -37.15% |
| 2017 Q2 | 9.3 Million USD | -4.59% |
| 2017 Q1 | 9.75 Million USD | -3.14% |
| 2017 Q3 | 8.17 Million USD | -12.14% |
| 2017 Q4 | 5.76 Million USD | -29.52% |
| 2016 Q3 | 11.69 Million USD | -37.04% |
| 2016 Q2 | 18.58 Million USD | 53.45% |
| 2016 Q4 | 10.06 Million USD | -13.95% |
| 2016 FY | 52.45 Million USD | -17.23% |
| 2016 Q1 | 12.1 Million USD | -46.94% |
| 2015 Q1 | 15.69 Million USD | 18.91% |
| 2015 Q4 | 22.82 Million USD | 114.11% |
| 2015 FY | 63.37 Million USD | 27.51% |
| 2015 Q2 | 14.2 Million USD | -9.52% |
| 2015 Q3 | 10.65 Million USD | -24.93% |
| 2014 FY | 49.7 Million USD | 78.19% |
| 2014 Q4 | 13.19 Million USD | 1.12% |
| 2014 Q3 | 13.05 Million USD | -2.14% |
| 2014 Q2 | 13.33 Million USD | 31.8% |
| 2014 Q1 | 10.11 Million USD | -1.67% |
| 2013 Q3 | 6 Million USD | -9.04% |
| 2013 Q2 | 6.59 Million USD | 31.79% |
| 2013 Q4 | 10.29 Million USD | 71.47% |
| 2013 Q1 | 5 Million USD | -3.17% |
| 2013 FY | 27.89 Million USD | 31.88% |
| 2012 Q3 | 4.88 Million USD | 2.29% |
| 2012 FY | 21.15 Million USD | -7.65% |
| 2012 Q4 | 5.16 Million USD | 5.77% |
| 2012 Q1 | 6.31 Million USD | -10.58% |
| 2012 Q2 | 4.77 Million USD | -24.35% |
| 2011 Q3 | 4.95 Million USD | 26.73% |
| 2011 FY | 22.9 Million USD | 35.92% |
| 2011 Q4 | 7.06 Million USD | 42.43% |
| 2011 Q1 | 6.87 Million USD | 194.46% |
| 2011 Q2 | 3.91 Million USD | -43.04% |
| 2010 FY | 16.85 Million USD | -1.72% |
| 2010 Q1 | 4.69 Million USD | 3.83% |
| 2010 Q4 | 2.33 Million USD | -50.29% |
| 2010 Q2 | 5.13 Million USD | 9.43% |
| 2010 Q3 | 4.69 Million USD | -8.57% |
| 2009 Q4 | 4.51 Million USD | 18.77% |
| 2009 Q2 | 3.29 Million USD | -40.48% |
| 2009 FY | 17.14 Million USD | -22.15% |
| 2009 Q1 | 5.53 Million USD | 9.89% |
| 2009 Q3 | 3.8 Million USD | 15.54% |
| 2008 Q2 | 5.71 Million USD | -25.4% |
| 2008 FY | 22.02 Million USD | -35.07% |
| 2008 Q4 | 5.03 Million USD | 39.56% |
| 2008 Q3 | 3.6 Million USD | -36.92% |
| 2008 Q1 | 7.66 Million USD | -13.46% |
| 2007 Q4 | 8.85 Million USD | 16.89% |
| 2007 FY | 33.91 Million USD | 72.47% |
| 2007 Q1 | 6.49 Million USD | 12.25% |
| 2007 Q2 | 10.76 Million USD | 65.76% |
| 2007 Q3 | 7.57 Million USD | -29.61% |
| 2006 Q4 | 5.78 Million USD | 48.17% |
| 2006 Q2 | 5.64 Million USD | 30.17% |
| 2006 Q3 | 3.9 Million USD | -30.8% |
| 2006 Q1 | 4.33 Million USD | 8.82% |
| 2006 FY | 19.66 Million USD | 25.03% |
| 2005 Q4 | 3.98 Million USD | 12.43% |
| 2005 Q3 | 3.54 Million USD | -22.86% |
| 2005 Q2 | 4.59 Million USD | 27.25% |
| 2005 Q1 | 3.6 Million USD | 24.75% |
| 2005 FY | 15.72 Million USD | 12.2% |
| 2004 Q1 | 3.93 Million USD | 47.46% |
| 2004 Q4 | 2.89 Million USD | 1.41% |
| 2004 Q2 | 4.33 Million USD | 10.37% |
| 2004 Q3 | 2.85 Million USD | -34.26% |
| 2004 FY | 14.01 Million USD | 23.2% |
| 2003 Q1 | 869.29 Thousand USD | -66.27% |
| 2003 FY | 11.37 Million USD | 96.93% |
| 2003 Q4 | 2.66 Million USD | -6.63% |
| 2003 Q3 | 2.85 Million USD | -42.73% |
| 2003 Q2 | 4.98 Million USD | 473.67% |
| 2002 Q3 | 2.23 Million USD | 107.06% |
| 2002 Q2 | 1.08 Million USD | -17.4% |
| 2002 Q1 | 1.3 Million USD | -7.85% |
| 2002 Q4 | 2.57 Million USD | 15.1% |
| 2002 FY | 5.77 Million USD | 9.84% |
| 2001 Q3 | 1.14 Million USD | -6.33% |
| 2001 Q1 | 1.32 Million USD | 10.15% |
| 2001 Q4 | 1.42 Million USD | 24.0% |
| 2001 FY | 5.26 Million USD | 16.24% |
| 2001 Q2 | 1.22 Million USD | -7.87% |
| 2000 Q3 | 963.97 Thousand USD | -10.55% |
| 2000 Q1 | 1.29 Million USD | -70.88% |
| 2000 FY | 4.52 Million USD | -72.84% |
| 2000 Q4 | 1.2 Million USD | 25.02% |
| 2000 Q2 | 1.07 Million USD | -17.1% |
| 1999 Q2 | 3.2 Million USD | -11.11% |
| 1999 FY | 16.66 Million USD | 61.79% |
| 1999 Q4 | 4.46 Million USD | -18.84% |
| 1999 Q3 | 5.5 Million USD | 71.88% |
| 1999 Q1 | 3.6 Million USD | 125.0% |
| 1998 Q4 | 1.6 Million USD | -44.83% |
| 1998 FY | 10.3 Million USD | -32.24% |
| 1998 Q1 | 2.3 Million USD | -46.51% |
| 1998 Q2 | 3.6 Million USD | 56.52% |
| 1998 Q3 | 2.9 Million USD | -19.44% |
| 1997 Q1 | 2.7 Million USD | -6.9% |
| 1997 Q4 | 4.3 Million USD | 0.0% |
| 1997 Q3 | 4.3 Million USD | 59.26% |
| 1997 Q2 | 2.7 Million USD | 0.0% |
| 1997 FY | 15.2 Million USD | 83.13% |
| 1996 Q3 | 1.6 Million USD | -11.11% |
| 1996 Q2 | 1.8 Million USD | -14.29% |
| 1996 Q1 | 2.1 Million USD | -27.59% |
| 1996 FY | 8.3 Million USD | -25.89% |
| 1996 Q4 | 2.9 Million USD | 81.25% |
| 1995 Q3 | 2.7 Million USD | -12.9% |
| 1995 Q2 | 3.1 Million USD | 19.23% |
| 1995 Q1 | 2.6 Million USD | -10.34% |
| 1995 FY | 11.2 Million USD | 4.67% |
| 1995 Q4 | 2.9 Million USD | 7.41% |
| 1994 Q1 | 2.5 Million USD | 0.0% |
| 1994 Q3 | 2.5 Million USD | -7.41% |
| 1994 Q2 | 2.7 Million USD | 8.0% |
| 1994 FY | 10.7 Million USD | 35.44% |
| 1994 Q4 | 2.9 Million USD | 16.0% |
| 1993 Q3 | 2.2 Million USD | 29.41% |
| 1993 Q1 | 1.6 Million USD | -11.11% |
| 1993 Q2 | 1.7 Million USD | 6.25% |
| 1993 Q4 | 2.5 Million USD | 13.64% |
| 1993 FY | 7.9 Million USD | 54.9% |
| 1992 Q4 | 1.8 Million USD | 28.57% |
| 1992 Q3 | 1.4 Million USD | 27.27% |
| 1992 Q2 | 1.1 Million USD | 10.0% |
| 1992 Q1 | 1 Million USD | 11.11% |
| 1992 FY | 5.1 Million USD | 96.15% |
| 1991 FY | 2.6 Million USD | 85.71% |
| 1991 Q4 | 900 Thousand USD | 50.0% |
| 1991 Q1 | 500 Thousand USD | 350.0% |
| 1991 Q2 | 500 Thousand USD | 0.0% |
| 1991 Q3 | 600 Thousand USD | 20.0% |
| 1990 Q4 | -200 Thousand USD | -150.0% |
| 1990 Q3 | 400 Thousand USD | -20.0% |
| 1990 Q1 | 600 Thousand USD | 130.0% |
| 1990 Q2 | 500 Thousand USD | -16.67% |
| 1990 FY | 1.4 Million USD | -46.15% |
| 1989 FY | 2.6 Million USD | -60.61% |
| 1989 Q3 | 800 Thousand USD | 0.0% |
| 1989 Q2 | - USD | 0.0% |
| 1989 Q1 | - USD | 100.0% |
| 1989 Q4 | -2 Million USD | -350.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -185.435% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 24.4% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 87.102% |
| Nascent Biotech, Inc. | 2.22 Million USD | -70.942% |
| Rebus Holdings, Inc. | 664 Thousand USD | -474.065% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 89.769% |
| Qrons Inc. | 643.67 Thousand USD | -492.19% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -878.471% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 93.364% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -817.445% |
| Skye Bioscience, Inc. | 13.54 Million USD | 71.864% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 95.608% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 22.492% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1356.405% |
| SQZ Biotechnologies Company | 85.61 Million USD | 95.548% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -30.709% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -153.798% |
| Mesoblast Limited | 5.9 Million USD | 35.415% |
| Marizyme, Inc. | 19.23 Million USD | 80.188% |
| Genus plc | 147.7 Million USD | 97.419% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 56.582% |
| Pharming Group N.V. | 225.49 Million USD | 98.31% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -86.059% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -184.134% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 54.29% |
| ContraFect Corporation | 56.88 Million USD | 93.3% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 13.539% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -157.771% |
| IMV Inc. | 37.7 Million USD | 89.892% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -36.606% |
| MultiCell Technologies, Inc. | 567.42 USD | -671675.933% |
| ONE Bio Corp. | 6.44 Million USD | 40.846% |
| Accustem Sciences Inc. | 3.74 Million USD | -1.745% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 95.565% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -616.553% |
| Q BioMed Inc. | 3.43 Million USD | -10.917% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 84.577% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -45.072% |
| Biomind Labs Inc. | 994.18 Thousand USD | -283.41% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 96.163% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -116.619% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 43.26% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -104.455% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 15347.164% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 76.192% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -107.716% |
| GB Sciences, Inc. | 1.42 Million USD | -168.34% |
| Alpha Cognition Inc. | 9.7 Million USD | 60.726% |
| HST Global, Inc. | 140.9 Thousand USD | -2605.182% |
| CSL Limited | 3.44 Billion USD | 99.889% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -238.853% |
| Halberd Corporation | 74.84 Thousand USD | -4993.118% |
| Enzolytics Inc. | 2.17 Million USD | -74.892% |
| Agentix Corp. | 1.37 Million USD | -177.877% |
| Resverlogix Corp. | 12.71 Million USD | 70.014% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -4.412% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.751% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -265.114% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -58.499% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -141.351% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -11.948% |
| AVAX Technologies, Inc. | 7.31 Million USD | 47.857% |
| Zenith Capital Corp. | 8.94 Million USD | 57.377% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.538% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -21780.437% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -55.246% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -2122.502% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -98.437% |
| Kadimastem Ltd | 2.41 Million USD | -58.158% |
| Helix BioMedix, Inc. | 1.97 Million USD | -93.292% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 64.923% |
| BioStem Technologies, Inc. | 22.97 Million USD | 83.409% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -2000.334% |
| Cell Source, Inc. | 4.32 Million USD | 11.873% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -312.75% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -312.75% |
| NovAccess Global Inc. | 2.46 Million USD | -54.526% |
| Affymax, Inc. | 39.38 Million USD | 90.322% |
| Itoco Inc. | 919.14 Thousand USD | -314.711% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 10.066% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -240.643% |
| Mobile Lads Corp. | 554.54 Thousand USD | -587.371% |
| CytoDyn Inc. | 18.05 Million USD | 78.891% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -15044.785% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1632.018% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -168.475% |
| SYBLEU INC | 160.87 Thousand USD | -2269.397% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -109.863% |
| International Stem Cell Corporation | 5.27 Million USD | 27.684% |
| Bioxytran, Inc. | 3.82 Million USD | 0.219% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -7140.969% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -18637.605% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 89.489% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -135.587% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -418.023% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -22.526% |
| Neutra Corp. | 243.82 Thousand USD | -1463.356% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 78.165% |
| PureTech Health plc | 144.59 Million USD | 97.364% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 81.397% |
| IXICO plc | 4.7 Million USD | 19.019% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 56.669% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 96.763% |
| CSL Limited | 3.89 Billion USD | 99.902% |
| Cellectis S.A. | 97.32 Million USD | 96.083% |